Isothermal Nucleic Acid Amplification Technology Market size to exceed $2.8bn by 2028

Published Date: April 19, 2022

Isothermal Nucleic Acid Amplification Technology (INAAT) Market size is set to surpass USD 2.8 billion by 2028, according to a new research report by Global Market Insights Inc.

Rising incidence of infectious chronic disease and growing demand for personalized medicines are some of the key factors will drive the market expansion. Increasing funding in R&D activities undertaken by biopharmaceutical as well as pharmaceutical companies will spur the market progress. New product launches coupled with surging government initiatives to enhance the overall biotech sector in emerging economies is projected to foster the INAAT market landscape.

Surging demand for blood transfusion will augment market revenue

Demand for blood transfusion is high across the globe owing to large patient population undergoing surgical procedures and suffering from chronic diseases. Additionally, with introduction of technologically advanced products and surging shift towards automation of instruments is also anticipated to propel the market statistics. For instance, with the introduction of the nucleic acid amplification test (NAT) for molecular disease screening and blood type, has resulted in increased efficiency and shorter turnaround times. As a result, more automated equipment are being used by blood banks and hospitals, boosting the market trends.

High demand for helicase-dependent amplification (HDA) will positively impact the industry expansion

Isothermal nucleic acid amplification technology market from helicase-dependent amplification (HDA) segment surpassed USD 76 million in 2021. HDA has various advantages over existing isothermal DNA amplification methods, as it has simple reaction scheme and has the ability to complete the entire process at a constant temperature. These properties offer a great potential for the development of DNA diagnostic instruments for use in the field and at the point-of-care. Therefore, several advantages associated with the HDA will fuel the market progression.

Browse key industry insights spread across 160 pages with 235 market data tables & 14 figures & charts from the report, “Isothermal Nucleic Acid Amplification Technology (INAAT) Market Analysis By Technology (Loop-mediated Isothermal Amplification [LAMP], Helicase-dependent Amplification [HDA], Nucleic Acid Sequence-based Amplification [NASBA], Strand Displacement Amplification [SDA]), By Product (Instruments, Reagents), Application, (Infectious Disease {HIV, Influenza, Malaria, Tuberculosis}, Oncology, Blood Screening), End-use (Hospitals, Diagnostic Laboratories), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2028” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/isothermal-nucleic-acid-amplification-technology-market

Presence of advanced and innovative kits will stimulate the industry statistics

INAAT market from reagents segment accounted for 71% revenue share in 2021. Many people prefer self-testing reagents kits because they are easy to use, do not require a technician, and provide quick results. Beside this, reagents are gaining immense demand in the area of cancer diagnostics as patients’ inclination toward non-invasive tests is significantly high, thereby positively influencing its market trends.

Presence of advanced and innovative equipment will generate the market revenue

Infectious disease segment is projected to witness over 11.7% CAGR through 2022 to 2028. The cases of infection such as influenza, tuberculosis are on surge globally. Additionally, key market players have launched INAAT kits for detection of influenza. This is a nucleic acid-based assay used for qualitative detection and discrimination of influenza A, B and RSV viruses using nasopharyngeal swab. Such scenarios will foster the isothermal nucleic acid amplification technology market demand.

Presence of advanced instruments and trained professionals in diagnostic laboratories will boost the business development

Diagnostic laboratories segment exceeded USD 381 million in 2021. Presence of advanced technology and instruments in these labs helps in obtaining absolute accuracy. For instance, Advanced Research and Diagnostics Laboratory of University of Minnesota is equipped with high-volume immunoassay testing platforms and mass spectrometer center.  Moreover, increased usage of kits, and diagnostic instruments for research purpose will propel the market share.

Government funding in European countries will spur the market progress

Europe isothermal nucleic acid amplification technology market is expected to grow at 10.8% CAGR over the forecast period. Growing prevalence of infectious diseases and increasing demand for point of care testing has led to increased demand for INAAT tests. Besides, increasing R&D efforts and government investment will ensure the region's market advancement. Furthermore, the presence of established healthcare infrastructure, as well as a surging number of pathology centres and hospitals for providing better patient management and access to improved care is the major aspect proving beneficial for the regional industry expansion.

Strategic initiatives undertaken by market participants will provide them competitive advantage

Some of the key market players operating in the INAAT industry include BD, Abbott (Alere), BioMerieux SA, Eiken Chemical Co. Ltd, Hologic Inc. (Gen-Probe), Lucigen, Meridian Bioscience, Inc., OptiGene Limited, Qiagen NV, Quidel Corporation, Tecan Genomics Inc., Grifols S.A., Thermo Fisher Scientific Inc., and Ustar Biotechnologies Ltd.  These industry participants are implementing various growth strategies with continued innovations and technology improvements to sustain competition in the business.